# Gene Therapy for Wet Age-Related Macular Degeneration

## TL;DR

This paper discusses how gene therapy could offer a long-term treatment for wet age-related macular degeneration, a condition affecting millions of people.

## Contribution

The paper provides recent updates on gene therapy trials for wet AMD, highlighting potential durable treatment options.

## Key findings

- The prevalence of wet AMD is projected to reach 82 million in the US by 2050.
- Gene therapy may offer a sustainable alternative to frequent anti-VEGF injections for treating wet AMD.
- Ongoing advancements in gene therapy biomechanism could improve treatment outcomes for wet AMD patients.

## Abstract

The prevalence of wet age-related macular degeneration (AMD) in the US is expected to increase to 82 million by 2050. Addressing the specialized needs for this population will become increasingly challenging as prevalence rises. Frequent anti-vascular endothelial growth factor (anti-VEGF) injections have been the recourse for this population; however, the burden wet AMD places on patients underscores the critical need for durable therapeutic approaches. Gene therapy is a bioengineered treatment that has transformed the management of previously untreatable disorders. Ongoing advancements and refinements in its biomechanism could lead to more sustainable treatment options for wet AMD. In this article, we provide recent updates on gene therapy trials for wet AMD.